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Definition
Bronchiolitis is a viral-induced lower respiratory 
tract infection that mainly occurs in children <1 year 
of age.
Causative organisms
The most frequent cause of severe bronchiolitis is respiratory 
syncytial virus (RSV). Other respiratory viruses are less common 
(parainfluenza virus, human metapneumovirus, influenza virus, 
measles virus), or definitive attribution has yet to be established (e.g. 
rhinovirus, bocavirus and coronavirus).
Seasonality
In South Africa bronchiolitis peaks in the RSV season, which 
varies slightly by province. RSV circulation is evident from 
February through to June, before the influenza season (May - 
September). 
Diagnosis
Clinical manifestations
Bronchiolitis is diagnosed on the basis of clinical signs and symp-
toms. In a young child, the clinical pattern of wheezing and hyper-
inflation is diagnostic and typically starts with an upper respiratory 
prodrome including rhinorrhoea, low-grade fever, cough and poor 
feeding, followed 1 - 2 days later by tachypnoea, hyperinflation and 
wheeze as a consequence of airway inflammation and air trapping.
The most reliable clinical feature of bronchiolitis is hyperinflation 
of the chest. 
The illness is generally self-limiting but may progress to more severe 
disease.
Measurement of the peripheral arterial oxygen saturation is 
useful to indicate the need for supplemental oxygen. A saturation of 
<92% at sea level and <90% inland indicates that the child requires 
admission to hospital for supplemental oxygen. 
Investigations
Chest X-rays are generally unhelpful and are not required in children 
with a clear clinical diagnosis of bronchiolitis. Haematological testing 
is not routinely required. Nasopharyngeal aspirates should not be 
routine, as viral testing adds little to routine management.
Management of bronchiolitis
Management is largely supportive. There is currently no proven 
effective therapy other than oxygen for hypoxic children (evidence 
A – well-designed randomised controlled clinical trial or diagnostic 
studies on relevant well-chosen populations), who can be given 
humidified low-flow oxygen (0.5 - 3 L/min) by nasal prongs. There is 
no evidence for routine use of antibiotics, nebulised agents (including 
bronchodilators, adrenaline, steroids or hypertonic saline), oral 
steroids, chest physiotherapy or montelukast (evidence A).
Prevention of RSV infection in  
high-risk children
Specific RSV monoclonal antibody, palivizumab, is available for 
children at particular risk of severe bronchiolitis (evidence A), as 
detailed below. 
Despite being so common, bronchiolitis remains poorly diagnosed and managed. This article is intended as an update on issues pertaining 
to this condition. 
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Indications for palivizumab for children at high 
risk of severe bronchiolitis
• Premature infants of gestational age <36 weeks at birth and
younger than 6 months of age at the start of the RSV season. 
Prophylaxis should be continued until the end of the RSV season 
(last dose in May). 
• Children of any gestation who are <24 months of age at the start
of the RSV season with any of the following: chronic lung disease 
of prematurity, chronic lung disease, primary immunodeficiency, 
haemodynamically significant congenital heart disease.
Note: Based on seasonality, prophylaxis should be started in January. 
If available, palivizumab prophylaxis for high-risk premature infants 
should commence prior to discharge from hospital. 
Education
Management of children with bronchiolitis requires that parents/
caregivers be educated about the condition. This is particularly 
important in the case of children who are not admitted to hospital, 
but is also beneficial before a child is discharged from hospital. The 
key elements of an education message are listed below.
Key elements of an education message for parents 
of children with bronchiolitis
• The condition has a prodrome of an upper respiratory tract
infection with low-grade fever.
• Symptoms are cough and wheeze, and often fast breathing.
• Bronchiolitis is caused by a virus; antibiotics are not needed.
• Bronchiolitis is usually self-limiting, although symptoms may
occur for up to 4 weeks in some children.
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